The French pharmaceutical company Sanofi agreed to buy the American company Principia Biopharma, which is developing drugs to treat immune diseases, for $ 100 in cash per share; The total value of the deal reaches 3.68 billion dollars.

According to Arabiyanet, Sanofi expects to submit a cash offer to buy the publicly traded Brisbane shares later this month.

Sanofi intends to finance the deal with its available cash. The company expects to complete the transaction during the last quarter of this year.

Sanofi of France and British GSK had announced earlier that they would receive $ 2.1 billion to fund a vaccine for Corona.

Sanofi Laboratories and GSK have announced a pledge to provide the British government with 60 million doses of the Covid-19 vaccine.

The two groups, which confirm that their vaccine will be licensed in the first half of 2021, said in a press release that active discussions are underway with the European Commission, France, Italy and other governments to ensure global reach To the vaccine, according to Euro News.

The British Business Affairs Minister Alok Sharma indicated, in a press release, that there is no guarantee that a vaccine will be found against the Corona virus one day, but he added that it is important to obtain On the ability to quickly access a wide range of promising potential vaccines.

This agreement is the fourth of its kind for the United Kingdom, and it has already concluded a deal with the multinational AstraZeneca and Valneva France, and an agreement with the alliance BioNTech / Pfizer .

The four agreements guarantee the country a total of 250 million doses of the expected vaccine.

Sanofi and GSK plan to start the first and second phase studies in September, followed by the third phase by the end of 2020.

It is reported that vaccine studies elsewhere in the world are in more advanced stages, of which only four formulations have entered the third stage of study, where their effectiveness is measured on a large scale.

The competition for vaccines is raging across the world. The United States has made an initial request for 100 million doses for 1.95 billion dollars, with the possibility of obtaining an additional 500 million doses from laboratories ...